COVID-19: Analysis of the Emerging Disease Landscape - March 2020
Summary The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space.The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions.
A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.
Scope - Global epidemiology metrics and trends
- Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
- Spotlight on social media coverage
Reasons to Buy - Global epidemiology metrics and trends
- Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
- Spotlight on social media coverage
Our reports have been used by over 10K customers, including:
The global liquid handling systems market is expected to reach USD 5.1 billion by 2026 from USD 4.0 billion in 2021, at a CAGR of 5.1% during the forecast period. The growth of this market is majorly driven by industrial growth in the pharma-biotech sector, rising R&D expenditure by biopharma companies, and growing life science research, supported...
The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research...
Middle East Respiratory Syndrome (MERS) (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2021, provides an overview of the Middle East Respiratory Syndrome (MERS)...
Rectal Cancer (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Drugs In Development, 2021, provides an overview of the Rectal Cancer (Oncology) pipeline landscape. Rectal cancer affects the lower part of the colon,...
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H1N1 Subtype...
Drug Addiction (Central Nervous System) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
Pharmaceutical
Drug Development
Biopharmaceutical
Healthcare
Infectious Disease
World
United States
Europe
APAC
Africa
Health Expenditure
Cancer Incidence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.